Condition
B ALL
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Recruiting2
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07441291Phase 3RecruitingPrimary
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
NCT04512716Early Phase 1Recruiting
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
NCT04723901Phase 1Unknown
Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia
NCT01219816Phase 2CompletedPrimary
Multi-centric Study
Showing all 4 trials